Michael Bengtson, M.D.
Associate Professor
Chief of Child and Adolescent Psychiatry
| Academic Contact Information |
USF Department of Psychiatry
3515 E. Fletcher Avenue
Tampa, FL 33613
Phone: (813) 974-5926
Email: mbengtso@health.usf.edu
|
| Education |
M.D., University of Alabama
|
| Professional Training |
General and Child Psychiatry, University of Florida
|
| Interests |
Autism and schizophrenia in children and adolescents
|
| Patient Care |
University Psychiatry Center
Call for Appointment: (813) 974-8900
|
| Biographical Sketch |
|
Dr. Bengtson received his MD from the University of Alabama School of Medicine, and did his general and child psychiatry training at the University of Florida.
He is board certified in general and child and adolescent psychiatry, and is currently an Associate Professor and Chief of Child Psychiatry in the Department of Psychiatry at the University of South Florida.
His areas of interest include, serious mental disorders impacting children and adolescents including autism and schizophrenia. Additionally he has been involved in research regarding the use and adverse effects of the antipsychotic medications often used in the treatment of serious mental disorders.
|
| Publications |
|
- Murphy TK, Bengtson MA, Tan JY, Carbonell E, Levin GM.
Selective Serotonin Reuptake Inhibitors in the Treatment of Pediatric Anxiety Disorders
A Review International Journal of Psychopharmacology (supplement 2 15, s47-63,2000)
- L Douglas Ried, Bernard T Renner, Michael A Bengtson, Brian M Wilcox, Wilfred W Acholonu Jr.
Weight Change After Atypical Antipsychotic Switch
Annals of Pharmacotherapy, 37, 2003.
- Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, Yang M.
Case series on the use of aripiprazole for Tourette syndrome
International Journal of Neuropsychopharacology, 8(3), 2005.
- Ried LD, Renner BT, McConkey JR, Bengtson MA, Lopez LM.
Increased cardiovascular risk with second generation antipsychotic agent switches
Journal of the American Pharmacists Association, 46 (4), 2006.
- Ried LD, McConkey JR, Bengtson MA, Garman PM, Hsu C, Rahnavard F.
Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia related disorders
Journal of the American Pharmacists Association, 47(2), 2007.
- Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.
Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia
Journal of the American Pharmacists Association, 47(3), 2007.
- Storch EA, Merlo LJ, Bengtson MA, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsch A, Fernandez M, Geffken GR, Goodman WK.
D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
International Journal of Clinical Psychopharmacology, 22, 2007.
- Leonard CM, Kuldau JM, Maron L, Ricciuti N, Mahoney B, Bengtson M, DeBose C.
Identical neural risk factors predict cognitive deficit in dyslexia and schizophrenia.
Neuropsychology. 2008 Mar;22(2):147-58. | |
